Search hospitals > Florida > Hollywood
Memorial Healthcare System
Claim this profileHollywood, Florida 33021
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Melanoma
Conducts research for Squamous Cell Carcinoma
54 reported clinical trials
9 medical researchers
Summary
Memorial Healthcare System is a medical facility located in Hollywood, Florida. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Melanoma, Squamous Cell Carcinoma and other specialties. Memorial Healthcare System is involved with conducting 54 clinical trials across 123 conditions. There are 9 research doctors associated with this hospital, such as Luis E. Raez, Delia C. Guaqueta, Atif Hussein, and Candice Sareli, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
ER negative
2Non-Small Cell Lung Cancer
Stage IV
Stage III
MET positive
Top PIs
Luis E. RaezMemorial Cancer Institute6 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Solid Tumors
11 reported clinical trials
19 drugs studied
Delia C. GuaquetaMemorial Regional Hospital/Joe DiMaggio Children's Hospital8 years of reported clinical research
Studies Breast Cancer
Studies Cancer
6 reported clinical trials
15 drugs studied
Atif HusseinMemorial Healthcare System7 years of reported clinical research
Studies Prostate Cancer
Studies Squamous Cell Carcinoma
6 reported clinical trials
27 drugs studied
Candice Sareli, MDMemorial Healthcare System3 years of reported clinical research
Studies Coronary Artery Disease
Studies Pleural Effusion
2 reported clinical trials
3 drugs studied
Clinical Trials running at Memorial Healthcare System
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Multiple Myeloma
Heart Failure
Breast Cancer
Plasma Cell Neoplasms
Cancer
Melanoma
Gallbladder Cancer
Bile Duct Cancer
BAY2927088
for Non-Small Cell Lung Cancer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: * BAY 2927088 twice every day as a tablet by mouth, or * Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will: * take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer * check the overall health of the participants by performing tests such as blood and urine tests, and checking * heart health using an electrocardiogram (ECG) * perform pregnancy tests for women * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Recruiting2 awards Phase 33 criteria
TBio-4101 + Pembrolizumab
for Advanced Solid Cancers
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
Recruiting1 award Phase 15 criteria
Brentuximab Vedotin + Pembrolizumab
for Advanced Cancers
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Recruiting1 award Phase 27 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Memorial Healthcare System?
Memorial Healthcare System is a medical facility located in Hollywood, Florida. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Melanoma, Squamous Cell Carcinoma and other specialties. Memorial Healthcare System is involved with conducting 54 clinical trials across 123 conditions. There are 9 research doctors associated with this hospital, such as Luis E. Raez, Delia C. Guaqueta, Atif Hussein, and Candice Sareli, MD.